Cue Biopharma to Host Business Update Call and Webcast
November 02 2023 - 8:00AM
Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage
biopharmaceutical company developing a novel class of T cell
engagers to selectively modulate tumor-specific T cells, announced
today that it will host a conference call and webcast to
provide a business and clinical update on Thursday, November 9,
2023 at 4:30 p.m. ET. Live and archived versions of the event can
be accessed via the Company’s website.
The Company will provide a clinical update from its Phase 1
trials evaluating the lead interleukin 2 (IL-2)-based biologic,
CUE-101, as monotherapy and in combination with KEYTRUDA®
(pembrolizumab) for patients with recurrent/metastatic HPV+ head
and neck cancer and from the ongoing Phase 1 trial with the
Company’s second IL-2 based candidate, CUE-102, for the treatment
of Wilms’ Tumor 1 (WT1) expressing cancers. Additional clinical,
pipeline and business updates will also be addressed.As a reminder,
posters highlighting new positive data from the CUE-101 and CUE-102
clinical programs will be presented at the Society for
Immunotherapy of Cancer’s 38th Anniversary Annual Meeting
(SITC 2023) on November 4, 2023.
Webcast Details
Thursday, November 9 at 4:30 p.m.
ET
Investors: |
1-888-886-7786 |
International
Investors: |
1-416-764-8658 |
Conference
ID: |
38547752 |
Request a return call via
the Call me™ link: |
https://emportal.ink/3RIYunz |
|
Participants can use guest
dial-in numbers above and be answered by an operator OR click the
Call me™ link for instant telephone access to the event. The link
will be active 15 minutes prior to the scheduled start time. |
Webcast: |
https://viavid.webcasts.com/starthere.jsp?ei=1638430&tp_key=eaa2024234 |
About Cue BiopharmaCue Biopharma, a
clinical-stage biopharmaceutical company, is developing a novel
class of injectable biologics to selectively engage and modulate
disease-specific T cells directly within the patient’s body. The
company’s proprietary platform, Immuno-STAT™ (Selective
Targeting and Alteration of T cells) and biologics are
designed to harness the body’s intrinsic immune system as T cell
engagers without the need for ex vivo manipulation or broad
systemic immune modulation.
Headquartered in Boston, Massachusetts, we are led by an
experienced management team and independent Board of Directors with
deep expertise in immunology and immuno-oncology as well as the
design and clinical development of protein biologics.For more
information please visit www.cuebiopharma.com and follow
us on Twitter at https://twitter.com/CueBiopharma.
Investor ContactMarie CampinellSenior Director,
Corporate CommunicationsCue Biopharma,
Inc.mcampinell@cuebio.com
Media ContactMaya RomanchukLifeSci
Communicationsmromanchuk@lifescicomms.com
Cue Biopharma (NASDAQ:CUE)
Historical Stock Chart
From Apr 2024 to May 2024
Cue Biopharma (NASDAQ:CUE)
Historical Stock Chart
From May 2023 to May 2024